A new wave of consolidation in the biotech sector: global laboratory analysis instrument specialist Quanterix has acquired Akoya Biosciences. AURIS Finance’s merger and acquisition experts provide an analysis.
Listed on NASDAQ with a market capitalization of $304 million, Quanterix is an American biotech company. Founded in 2007, the group specializes in the ultra-sensitive detection of protein biomarkers using its proprietary SiMoA (Single Molecule Array) technology. This cutting-edge innovation analyzes extremely low protein levels, up to 1,000 times more sensitive than traditional methods. Thanks to this technology, Quanterix holds a key position in research and diagnostics in oncology, neurology, cardiology, and infectious diseases. Focusing on precision medicine, Quanterix targets neurodegenerative diseases such as Alzheimer’s and Parkinson’s, as well as traumatic brain injuries and multiple sclerosis. To develop its innovative solutions, the group collaborates with research institutions and pharmaceutical companies, including Pfizer, Novartis, and AstraZeneca. In 2024, the company reported revenues of $137 million, up 12% year-over-year. Growth was largely driven by Quanterix’s Accelerator services—specialized laboratory services using its SiMoA technology—while instrument-related revenue declined, and consumables revenue remained stable.
Partnerships and Collaborations
By acquiring Akoya Biosciences, Quanterix gains a major player in the biotech sector. Akoya Biosciences, positioning itself as “The Spatial Biology Company,” aims to provide context to the world of biology and human health through the power of spatial phenotyping—a technology that analyzes and visualizes the organization and interactions of cells within their tissue context. Quanterix thus acquires fundamental expertise in developing new therapies. This strategic merger aims to create the first integrated solution for the ultra-sensitive detection of protein biomarkers in blood and tissues.
Birth of a Giant
In 2024, Akoya Biosciences generated $81.7 million in revenue, down 15.5% year-over-year. This acquisition allows Quanterix to access a market valued at $5 billion in neurology, immunology, and oncology, with an additional $10 billion opportunity in Alzheimer’s diagnostics. This major operation, which brings together two leading biotech players, was subject to regulatory approval. The transaction cleared a regulatory hurdle on February 24, 2025, when the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 expired without objection from antitrust authorities. This approval enables Quanterix and Akoya to proceed with the merger process, with completion expected in the second quarter of 2025.
Our Experts by Your Side
By combining Quanterix’s expertise in ultra-sensitive biomarker detection and Akoya’s spatial biology know-how, this strategic operation creates a major player capable of addressing multi-billion-dollar markets. In the biotech sector, mergers and acquisitions are now a key growth lever. AURIS Finance’s sector-specialized experts support you in your merger, acquisition, and fundraising operations. Contact us
